Sanofi invests to make France its world class center of excellence in vaccine research and production

SanofiSanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in responding to future pandemic risks. Aligned with its corporate strategy presented last December, Sanofi will invest €610 million to create a new production site and research center in France with both dedicated to vaccines.

"Sanofi's heart beats in France. We have a long history and exceptional teams working throughout the country, embodying our strong values. By investing in a new industrial site and a R&D center, Sanofi positions France at the core of its strategy, aiming to make France a world-class center of excellence in vaccine research and production," said Paul Hudson, Chief Executive Officer at Sanofi. "Sanofi is a major healthcare player in France, in Europe, and worldwide. It is our responsibility to focus our resources and expertise against the current pandemic, but also to invest in preparing for future ones. We welcome the ongoing collaboration and commitment of the French authorities who we have been working alongside with the last several months to achieve this."

Sanofi will invest in vaccine production in France and create its Evolutive Vaccine Facility (EVF) in Neuville sur Saône. This state-of-the-art industrial site will utilize the latest innovative vaccine production technologies. The project represents an investment of €490 million over a five-year period, and is expected to create 200 new jobs. Sanofi’s investment has been made possible thanks to the support and the close collaboration with French authorities over the last few months.

The building of this plant will enable Sanofi Pasteur, Sanofi's global entity dedicated to vaccines, to be the first pharmaceutical manufacturer to benefit from such an industrial tool and to secure vaccine supplies in the event of new pandemics. EVF is a new type of factory designed around a central unit housing several fully digital production modules that make it possible to produce three to four vaccines simultaneously, versus only one in current industrial sites. This modularity will make it possible to prioritize the production of a specific vaccine in a more timely manner based on public health issues.

Sanofi has also committed to investing €120 million to create a new R&D center in France at the Sanofi Pasteur site in Marcy-l'Etoile to develop future vaccines. This state-of-the-art digital facility will house highly specialized laboratories that will enable the development of vaccines against emerging diseases and pandemic risks. The facility will become a world reference for pre-clinical research and pharmaceutical and clinical development. Sanofi expresses its gratitude to the Auvergne-Rhône-Alpes French region for its support in this project.

Sanofi shares the French authorities’ vision for a sovereign Europe in healthcare and announced last February the creation of a new industry-leading European company to provide active pharmaceutical ingredients. The company today stands ready to cooperate with France and the European Union (EU) on other projects which will provide the EU with extra vaccine (EVF extension project) or monoclonal antibody (cell culture tanks installation and start-up project) production capabilities. These supplementary capabilities can be leveraged by the EU and other pharma companies in the event of a healthcare crisis.

A world leader in vaccines

Sanofi, with its global vaccine entity Sanofi Pasteur, is a leading vaccine developer and manufacturer. Sanofi offers a portfolio of vaccines to protect children, adolescents, and adults from diseases such as influenza, infectious diseases, and endemic diseases.

With 16,000 employees and an international network of 12 industrial sites dedicated to vaccine manufacturing, including three in France (Marcy-l'Etoile, Neuville sur Saône, Val-de-Reuil), Sanofi Pasteur’s vaccines protect more than half a billion people in the world.

Sanofi is the world's third largest vaccine producer in value terms, with a unique footprint in the Rhône-Alpes region and nearly 7,200 employees working for the Sanofi Pasteur site in Lyon, a global center of excellence in the field of vaccines.

A major player in the healthcare sector in France

Sanofi plays a major role in meeting the health needs of patients and supporting their healthcare. In France, Sanofi provides more than 200 medicines, vaccines, and health products.

With a unique footprint of 33 sites in France, including 22 industrial sites and approximately 25,000 employees, Sanofi represents a quarter of the workforce of the entire French pharmaceutical industry.

Sanofi is France's leading private R&D investor, with more than €2 billion spent each year researching new treatments for patients, totaling half of the private research effort in France. Nearly 5,000 researchers and scientists work in a variety of therapeutic areas, mainly focusing on oncology, immuno-oncology, vaccines and rare diseases.

Sanofi also has one third of its global production in France, making it one of the country’s leading exporters. Sanofi has invested €3 billion in its French production sites over the past five years, including €1.5 billion to accelerate the build-up of biotechnologies in the country.

On the front line in the fight against COVID-19

Since the beginning of the pandemic, Sanofi has played a leading role in the fight against COVID-19. In collaboration with health authorities and international partners, Sanofi is one of the only companies in the world to work on the search for COVID-19 vaccine candidates by exploring two different technological approaches.
  • The recombinant DNA technology, in collaboration with GSK, is a type of vaccine that makes it possible to industrially produce very large quantities of antigens, the proteins injected to stimulate the immune system’s response to the virus.
  • The messenger RNA technology technology, in collaboration with TranslateBio, is a vaccine that leads the human body’s cells to manufacture the virus antigens to which the immune system will react.

Sanofi is also committed to making its vaccine accessible to all and around the world.

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Most Popular Now

AstraZeneca COVID-19 vaccine Vaxzevria authorised …

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), formerly AZD1222, has been granted a special approval for emergency use in Japan for active immunisat...

Pfizer and BioNTech to supply the European Union w…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companie...

Takeda announces approval of Moderna's COVID-19 va…

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under...

Sanofi and GSK initiate global Phase 3 clinical ef…

Today, Sanofi and GlaxoSmithKline plc (GSK) started enrolment in their Phase 3 clinical study to assess the safety, efficacy and immunogenicity of their adjuvanted recomb...

Sanofi and GSK COVID-19 vaccine candidate demonstr…

The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody responses, in line with those measured in people who h...

European Commission approves Venclyxto-based combi…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto® (venetoclax) in combination with hypomethylating agents, azacitidi...

Novartis reaches milestone delivery of 1 billion c…

Novartis announced that it has delivered one billion courses of antimalarial treatment since 1999. More than 90% of this artemisinin-based combination therapy (ACT) was s...

COVID-19 mRNA vaccines are immunogenic in pregnant…

Pregnant women with symptomatic COVID-19 have a higher risk of intensive care unit admissions, mechanical ventilation and death compared to non-pregnant reproductive age ...

Why are some COVID-19 vaccines working better for …

MSU researcher is studying, raising awareness about the role of sex in the efficacy of vaccines that make use of nanomedicine. If there's one take-home message for the...

Rogue antibodies wreak havoc in severe COVID-19 ca…

The development of antibodies to the COVID-19 virus has been the great long-term hope of ending the pandemic. However, immune system turncoats are also major culprits in ...

New vaccine platform: 'Two-one replicon-and-VLP-mi…

To stop the current SARS-CoV-2 pandemic, vaccines of high quality, safety, and efficacy are required. Scientists of the Paul-Ehrlich-Institut and the Ludwig Maximilian Un...

COVID-19 monoclonal antibodies reduce risk of hosp…

Monoclonal antibodies, a COVID-19 treatment given early after coronavirus infection, cut the risk of hospitalization and death by 60% in those most likely to suffer compl...